Dr. Robert Boock is CEO/CTO of Glucovation.
Dr. Boock previously served as the Senior Technical Director of Research and Development at Dexcom. He was responsible at Dexcom for managing all long-term research including technology for their future generation sensor products.
He was responsible for development of materials for Dexcom’s SEVEN PLUS and invented the entire G4 PLATINUM sensor and led its development and commercialization.
He has over 20 years of medical device industrial experience and is an expert in materials and device/tissue interface and has invented and launched successful commercial products in numerous fields.
Dr. Boock received his Doctorate in Bioengineering from the University of Pennsylvania. He holds more than 44 patents and over 100 pending patents as well as having more than 25 peer reviewed journal articles.
Dr. Jeff Suri is Executive Vice President of Sensor Technologies and acting President for Glucovation.
Dr. Suri has over 13 years of experience developing and testing continuous glucose monitoring technologies and platforms. At Dexcom he served as a Senior Scientist where he led the hands-on development of next generation sensor technology. He played critical roles in fundamental membrane research, process development, and manufacturing of the G4 Platinum sensor.
Prior to Dexcom, Dr. Suri helped start GluMetrics, a company focused on developing a fluorescence-based glucose sensor for the critical care market. As Director of Chemistry and Sensor Technology he co-invented the core chemistry technology for a boronic acid-based glucose sensor.
Dr. Suri holds a PhD in organic chemistry from University of California, Santa Cruz. He carried out postdoctoral research at The Scripps Research Institute. Dr. Suri has presented at numerous conferences, has 4 issued patents in glucose sensing technology and over 20 publications in the fields of organic and polymer chemistry.
Kenneth San Vicente is Executive Vice President of Research and Development, Electronics and Software.
Kenneth previously served as a Principal Engineer at Dexcom. Most recently he was the systems architect and project lead for their latest generation transmitter/receiver system. He led a team responsible for building the sensor interface electronics, system firmware, glucose value generating algorithm, and wireless protocol definition/implementation on the transmitter and the corresponding receiver side wireless implementation and user interface cell phone application.
He has 30 years of experience in hardware/software systems development, and extensive medical device industry experience and commercial electronics industry experience.
Kenneth received his Bachelor’s in Mathematics and Computer Science from the University of California at Los Angeles and his Master’s in Business Administration from the University of California at Irvine and has 8 issued patents on wireless CGM systems.
Board of Directors
Mr. Baltera is a seasoned pharmaceutical industry executive and board member of several healthcare companies. Most recently, he was the CEO of Amira Pharmaceuticals, which was acquired by Bristol-Meyers Squibb Company for $325M upfront and $150M in future milestones. He was instrumental in focusing Amira’s development efforts, strengthening its pipeline and forging key collaborations with partners such as GlaxoSmithKline.
Before becoming Amira’s CEO, Mr. Baltera worked for 17 years at Amgen, during which time he held a number of senior management positions, the last being vice president of corporate and contract manufacturing. Mr. Baltera served as the team leader responsible for the approval of Kineret™ in rheumatoid arthritis, a highlight of his many accomplishments while at Amgen.
Mr. Baltera serves in senior roles in several organizations, including the Executive Chairman of the Board of Directors of Adheron Therapeutics, member Board of Directors Organovo Holdings (ONVO), member Board of Directors of Panmira Pharmaceuticals, member Board of Directors of San Diego Venture Group, and member the Board of Trustees of the Keck Graduate Institute.
Mr. Baltera has an M.B.A. from the Anderson School at UCLA and earned his B.S. in microbiology and a M.S. in genetics from The Pennsylvania State University. In 2013 Mr. Baltera was awarded the Eberly College of Science (Pennylvania State University) Outstanding Alumni Award.
Dr. Burd is a co-founder and General Partner of Sabur Technology. Previously Dr. Burd was Founder & CEO of Oculir, developing a remarkable new non-invasive glucose testing technology. Prior to Oculir, Dr. Burd was a General Partner of Windamere Venture Partners and Chairman & CEO of MiraMedica, a company developing computer-aided detection technology for enhanced cancer diagnosis. MiraMedica was sold to Kodak in August 2003. Dr. Burd was previously President & CEO of DexCom, where he directed the company’s work to develop, manufacture and market the first long-term implantable glucose sensor for people with diabetes. In April 2005, DexCom completed a successful IPO, valuing the company at up to $600 million.
Before founding DexCom, Dr. Burd was the Founder, President, CEO and Chairman of LXN Corporation, which developed and marketed the Duet® Diabetes Control System to healthcare professionals and the In Charge™ Diabetes Control System to the diabetes self-testing market. LXN was sold to Johnson and Johnson in 2000.
Previously, Dr. Burd held executive positions at QUIDEL Corporation, where he directed the development of enzyme immunoassay products for the clinical lab, physician’s office and OTC markets. Prior to joining QUIDEL, Dr. Burd was Executive Vice President and COO for MAST Immunosystems, Inc. where he was responsible for the company’s operations, including research and development, marketing, sales and finance. MAST Immunosystems was purchased by Hitachi Chemical in 1997. Previously, Dr. Burd was involved in other medical product research and development at Miles Laboratories, Inc. (now Bayer Corporation).
Dr. Burd has authored and co-authored numerous articles and his work in the medical and biotechnology field has led to the filing and ownership of twenty-three patents and the development of many innovative medical products. He is also the 2008 Recipient of the Edwin F. Ullman Award. He graduated from Purdue University with a B.S. in Biochemistry, and earned an M.S. and Ph.D., also in Biochemistry, from the University of Wisconsin.
Thomas A. Coll is a partner in the Cooley Business department and Head of the Business & Technology Practice Group in the Firm's San Diego office, where he resides. Mr. Coll joined the Firm in 1989, practicing in the San Francisco office until moving to San Diego as a founding member of that office in November 1991.
Mr. Coll's practice covers a broad range of general corporate matters, including counseling public and privately-held companies regarding disclosure and reporting requirements, technology licensing, equity incentives, employee compensation and benefits and the formation of new businesses. Mr. Coll also represents clients in a broad range of transactional matters, including public offerings, public and private company mergers and acquisitions, corporate partnering and licensing transactions, spin-offs and venture capital financings. He is counsel to public and private companies in a broad range of industries, with a focus on the computer hardware and software, telecommunications, biotechnology and medical products industries.
From 2007 - 2014, Mr. Coll was named to the Best Lawyers in America list in the categories of Biotechnology Law, Corporate Law, Leveraged Buyouts and Private Equity Law, and Venture Capital Law. He was also named to the 2012, 2011, 2010, 2009, 2008 and 2007 San Diego Super Lawyers list in the category of Business/Corporate Law.
Mr. Coll received a JD from the University of California, Berkeley School of Law (Boalt Hall), where he was a member of the Order of the Coif. He received his undergraduate degree from the University of California, Berkeley, in 1985, earning a BS, with highest honors in business administration with an emphasis in accounting and finance. He is a member of the State Bar of California, the American Bar Association and the San Diego County Bar Association. Mr. Coll was selected for the 2006 edition of The Best Lawyers in America for the Leveraged Buyouts and Private Equity Law category.
Carlos F. Barbas, III, Ph.D., is a Professor of The Scripps Research Institute, Departments of Cell and Molecular Biology and Chemistry and The Skaggs Institute for Chemical Biology. He holds the Janet and W. Keith Kellogg II endowed Chair. Dr. Barbas has received honors including the Investigator Award from the Cancer Research Institute, The Scholar Award of the American Foundation for AIDS Research, the Presidential Green Chemistry Challenge Award, the American Chemical Society Cope Scholar Award, the Tetrahedron Young Investigator Award for Bioorganic and Medicinal Chemistry, and The NIH Director’s Pioneer Award.
He is the author of over 335 publications and is a named inventor on 57 issued patents. Key accomplishments in the area of biotechnology, pioneered by Dr. Barbas and his colleagues, include the development of the first human antibody phage libraries, development of the first synthetic antibodies, the development of the first artificial transcription factors capable of regulating endogenous genes, and chemically programmed antibodies. Each of these approaches has resulted in a new drug class that is currently in clinical trials for the treatment of a variety of diseases and, in some cases, already validated with approved drugs.
Dr. Barbas is a founder of the biotechnology companies Prolifaron (acquired by Alexion Pharmaceuticals in 2000), CovX (acquired by Pfizer in 2008), and Zyngenia Inc. and the inventor of their underlying core technologies.
Dr. Barbas has pioneered the development of Organocatalysis and invented a number of key chemical reactions using this approach. His research interests have focused on the development of new therapeutic approaches to human diseases through studies at the interface of synthetic organic chemistry, molecular biology, and medicine.